Strata Critical Medical Q3 revenue up 36.7% to $49.3M; net loss widens to $9.7M

Strata Critical Medical, Inc.

2025-Q3 EPS reported $0.62 revenue$130,354,000

Revenue $49.3M, up 36.7% YoY; organic growth 29.0% excluding Keystone acquisition.
Net loss from continuing ops $(9.7)M, widened from $(5.6)M in prior-year period.
Medical Segment Adjusted EBITDA $7.6M, +93.5% YoY; margin 15.3% (up 450 bps).
Raised FY2025 revenue guidance to $185-195M; reaffirmed Adjusted EBITDA range.
Investor Day on Nov 17, 2025 to introduce FY2026 guidance and medium-term targets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.